XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.3
Disaggregated Revenues (Tables)
 9 Months Ended
Sep. 30, 2025
Disaggregation of Revenue [Abstract]  
Schedule of Disaggregation of Revenues
The following table provides information regarding total revenues (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
(unaudited)(unaudited)
Net product sales
Qelbree$81,416 $62,359 $223,708 $166,857 
GOCOVRI40,849 35,657 108,198 93,922 
APOKYN10,387 19,867 38,183 53,811 
Trokendi XR10,043 15,318 34,037 48,393 
Oxtellar XR12,016 29,805 33,851 86,265 
ONAPGO6,806 — 8,410 — 
Other(1)
7,025 7,296 22,138 22,053 
Total net product sales168,542 170,302 468,525 471,301 
Collaboration revenue (ZURZUVAE)(2)
20,164 — 20,164 — 
Royalty, licensing and other revenues3,397 5,387 18,691 16,357 
Total revenues$192,103 $175,689 $507,380 $487,658 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
(2) Includes the Company's proportionate share of net sales of ZURZUVAE.